Welcome, visitor! [ Login

Top 10 Pharma/Biotech M&A Deals in 2011 and 2010

Medical Blog 2012-07-14

Top 10 Pharma/Biotech M&A Deals in 2011 and 2010
Year Rank Acquiring Company Deal Type Target Deal Value ($bn) Status Financing Structure
2011 1 Takeda Company Acquisition Nycomed 13.1 Closed Cash
2 Gilead Sciences Company Acquisition Pharmasset 11.0 Closed Cash
3 Teva Pharmaceutical Industries Company Acquisition Cephalon 6.8 Closed Cash
4 Forest Laboratories Company Acquisition Clinical Data 1.3 Closed Cash
5 Alexion Pharmaceuticals Company Acquisition Enobia Pharma 1.0 Open Cash
6 Amgen Company Acquisition BioVex 1.0 Closed Cash
7 Alkermes Business Unit Elan Drug Technologies 1.0 Closed Share Exchange + Cash
8 Daiichi Sankyo Company Acquisition Plexxikon 0.9 Closed Cash
9 Teva Pharmaceutical Industries Majority Stake Taiyo Pharmaceutical Industry 0.9 Closed Cash
10 Shire Company Acquisition Advanced BioHealing 0.8 Closed Cash
2010 1 Novartis Majority Stake + Company Acquisition Alcon 38.0 Closed Share Exchange + Cash
2 Sanofi Company Acquisition Genzyme 20.1 Closed Cash
3 Teva Pharmaceutical Industries Company Acquisition ratiopharm 5.0 Closed Cash
4 Valeant Pharmaceuticals International Company Acquisition Biovail 4.5 Closed Share Exchange + Cash
5 Astellas Pharma Company Acquisition OSI Pharmaceuticals 4.0 Closed Cash
6 Abbott Laboratories Business Unit Piramal Healthcare Solutions business 3.8 Closed Cash
7 Pfizer Company Acquisition King Pharmaceuticals 3.6 Closed Cash
8 Grifols Company Acquisition Talecris Biotherapeutics 3.4 Closed Share Exchange + Cash
9 Celgene Company Acquisition Abraxis BioScience 2.9 Closed Share Exchange + Cash
10 Johnson & Johnson Company Acquisition Crucell 2.2 Closed Cash

All data sourced to EvaluatePharma.

More : http://adf.ly/FPEVU

3054 total views, 1 today

全球医药业并购 Pharmaceutical M&A deals in 2009

Medical Blog 2012-07-14

Following 2008, when pharmaceutical sector merger and acquisition activity was on a relatively small scale in terms of the size of deals announced, 2009 was a bumper year.

According to The Pharma Letter’s records, there were 92 pharmaceutical acquisitions consummated during 2009 (with several others announced but failing), compared with 113 the previous year. Of the 2009 announcements, 16 deals exceeded a value of $1 billion (see separate story for a full commentary on the deals.) The full list can be seen below.

 

Company Partner Deal value $ Complete
Abbott Labs (US) Advanced Medical Optics (US) $2.8 billion Feb 2009
Abbott (US) Visiogen $400.0 million Oct 2009
Abbott (US) Solvay (Belgium) Pharma unit $6.6 billion 1st-qtr 2010
Adamis Pharma (USA) La Jolla Pharma Undisclosed TCB
Alcon (Swiss) ESBATech (Swiss) $439.0 million TBC
AstraZeneca (UK) Novexel (France) $505.0 million TCB
BioMarin (US) Huxley Pharma (US) c$58.5 million Oct 2009
BioSante Pharma (US) Cell Genesys (US) $38.0 million Oct 2009
Biovitrum (Sweden) Swedish Orphan (Sweden) $493.0 million Dec 2009
Bristol-Myers Squibb (US) Medarex (US) $2.4 billion Sep 2009
Celgene (US) Gloucester Pharma (US) $640.0 million 1st-qtr2010
Cellidex Thera (US) CuraGen (US) $94.5 million Oct 2009
Cephalon (US) Arana Therapeutics (Australia) $205.0 million Aug 2009
Dainippon Sumitomo (Japan) Sepracor (US) $2.6 billion Oct 2009
Deerfield Management NitroMed (US) $36.0 million Feb 2009
Eisai (Japan) AkaRx (US) $255.0 million TBC
Endo Pharma (US) Indevus Pharma (US) $637.0 million Feb 2009
Evolva (Swiss) Arpida (Swiss) Undisclosed Dec 2009
Evotec (Germany) RSIPL (India) $3.5 million Aug 2009
Genesis Pharma (US) Hongrui Pharma (China) $16.0 million Mar 2009
Gen-Probe (US) Tepnel Life Science (UK) $132.2 million Apr 2009
Gilead Sciences (US) CV Therapeutics (US) $1.4 billion Apr 2009
GlaxoSmithKline (UK) Bristol-Myers Squibb (Pakistan) $365.0 million 2009
GlaxoSmithKline UK) UCB Emerging Market units $676.0 million 2009
GlaxoSmithKline (UK) Stiefel Labs (US) $3.6 billion July 2009
GlaxoSmithKline (UK) Aspen Pharmacare (19% stake) $593.6 million est Dec 2009
GlaxoSmithKline (UK) Intercell (Austria; 5% stake) $57.4 million Dec 2009
GPC Biotech (German) Agennix (US) Undisclosed Mar 2009
HalcyGen (Australia) Mayne Pharma Int (Australia) 415.0 million Oct 2009
Hard to Treat Medicine (China) Shenzen Mellow Hope (China) Undisclosed Mar 2009
Helsinn (Switzerland) Sapphire Therapeutics Undisclosed Feb 2009
Hisamitsu Pharma (Japan) Noven Pharma (US) $428.0 million Aug 2009
Hospira (US) Orchid Chem & Pharma (India) (injectable generics business) $400.0 million TBC
Integrated DNA Tech (US) VH Bio’s oligo business Undisclosed 2009
Inviragen (US) SingVax (Singapore) Undisclosed Oct 2009
Johnson & Johnson (US) Cougar Biotechnology $1.0 billion Jul 2009
Johnson & Johnson (US) Crucell – 18% stake $443.3 million Sept 2009
Laboratory Corp of America (US) Monogram Biosciences (US) $106.7 million Aug 2009
LEO Pharma (Denmark) Peplin (US, Australia) $287.5 million Nov 2009
Ligand Pharma (US) Neurogen (US) $11.6 million Dec 2009
Ligand Pharma (US) Metabasis Thera (US) $3.2 million Nov 2009
Lundbeck (Denmark) Ovation Pharma (US) $900.0 million Mar 2009
Lundbeck (Denmark) LifeHealth (UK) $147.0 million Jul 2009
Medicines Co (US) Targanta Therapeutics $42.0 million Feb 2009
MediciNova (US) Avigen (US) $37.0 million Dec 2009
Merck & Co (US) Schering-Plough (US) $41.1 billion Nov 2009
Merck & Co (US) Avecia Biologics (UK) Under $1 billion TBC
Merck KGaA (Germany) Bangalore Genei (India) Undisclosed Oct 2009
Midas BidCo (Goldshield management team) Goldshield (UK) $280 million Dec 2009
Mylan (US) Matrix Labs (India) (29% not already owned) $133.0 million 2009
Myriad Pharma (US) Javelin Pharma (US) $96.0 million TBC
Nippon Chemiphar (Japan) Nihon Pharma (taking over Ranbaxy share of the JV) Undisclosed TCB
Novartis (Swiss) EBEWE Pharma (Austria) $1.2 billion Sept 2009
Novartis (Swiss) Zheijian Tianyuan (China) $125 million TBC
Novartis (Swiss) Corthera (US) $120.0 million (Plus possible $500 million on milestone successes) TCB
Onyx Pharma US) Proteolix (US) $850.0 million Nov 2009
Opko Health (US) Pharma Genexx (Chile) $16.0 million Dec 2009
OXiGENE (US) VaxGen (US) $22.0 million TBC
Pfizer (US) Wyeth (US) $68.0 billion Oct 2009
Pharmexa (Denmark) Affitech (Norway) Merger Jun 2009
Piramel (India) Minrad International (US) $40.0 million 2009
PPD (US) Magen Biosciences (US) $14.5 billion Apr 2009
Progen (Australia) Avexa (Australia) $55.3 million 2009
Proximagen Neuro (UK) Cambridge Biotech (UK) (acquired from Biovitrum of Sweden) Undisclosed Nov 2009
Qiagen (Netherlands) SA Biosciences (US) $90.0 million Dec 2009
Raptor Pharma (US) TorreyPines (US) Undisclosed Sept 2009
Roche (Swiss) Genentech (USA) $46.8 billion (42% not already owned) Apr 2009
Sanofi-Aventis (France) Zentiva (Czech) $2.3 billion Mar 2009
Sanofi-Aventis (France) Medley SA (Brazil) $220.0 million Mid-2009
Sanofi-Aventis (France) Laboratorios Kendrick (Mexico) Undisclosed Apr 2009
Sanofi-Aventis (France) BiPar Sciences (US) Undisclosed 2nd qtr
Sanofi-Aventis (France) Shantha Biotechnics (India) $613 million Aug 2009
Sanofi-Aventis (France) Fovea Pharma (France) $542 million Dec 2009
Sanofi-Aventis (France) Chattem (US) $1.9 billion TCB
Santhera (Swiss) Juvantia Pharma Undisclosed Oct 2009
Schwabe Pharma (German) Dr Peithner Holdings Undisclosed May 2009
Sigma-Tau (Italy) Enzon (US) Specialty Pharma business $327.0 million Dec 2009
Silence Therapeutics UK) Intradign (US) Undisclosed Jan 2010
Simcere Pharma (China) Jiansu Yanshen (China) 37% stake $28.6 million 2009
Sinclair Pharma (UK) Lab Novo Pharma (Spain) Remaining 50% holding Undisclosed Feb 2009
Stem Cells (USA) Stem Cells Sciences (UK) Undisclosed May 2009
Takeda (Japan) IDM Pharma (US) $75.0 million July 2009
Teva (Israel) OncoGenex (US) (small stake) $10.0 million TCB
Teva (Israel) Taisho Pharma Ind (Japan) (majority stake min.66.7%) Undisclosed Dec 2009
Tolmar (US) Zila (US) $4.0 million Sept 2009
Tolmar (USA) QLT (Canada)’s US unit $230.0 million Oct 2009
Tongjitang (China) Anhui Jingfanag (China) $8.8 million Apr 2009
Valeant (US) EMO-PHARMA (Poland) $28.0 million May 2009
Valeant (USA) Lab Dr Renaud (Canada) $21.8 million TCB
Warner Chilcott (Irish) Procter & Gamble Rx Pharma business $3.2 billion Oct 2009
Watson Pharma (US) Arrow Pharma (US) $1.75 billion Dec 2009
Wyeth (US) Thiakis (UK) $150.0 million Jan 2009

3215 total views, 1 today

全球制药业并购 2011 Pharmaceutical M&A deals in 2011

Medical Blog 2012-07-14

 

Pharmaceutical M&A deals in 2011

Details for the 129 M&A announcements recorded by The Pharma Letter are provided in the full table below:
Compared with 117 in 2010, which was then a record number (Pharmaceutical M&A deals in 2010, The Pharma Letter January 13, 2011).

 

Company

  

Takeover candidate

  

 

Deal Value US $ *

  

 

Completed

  

 

Abcam (UK) 

 

MitoSciences (UK) 

 

Undisclosed 

 

May-11 

 

Abcam (UK) 

 

Ascent Scientific (UK) 

 

$15.9 million 

 

Sep-11 

 

Acino Pharma (Switz) 

 

Mepha (Switz) MENA, Latin America and Asia business units from Teva subsidiary Cephalon 

 

$226.0 million 

 

Dec-11 

 

ADVENTRX Pharma (US) 

 

SynthRx (US) 

 

Undisclosed stock deal 

 

Apr-11 

 

Affymetrix (US) 

 

eBioscience (US) 

 

$330.0 million 

 

Dec-11 

 

Alere (US) 

 

Axis-Shield (UK) 

 

$365.0 million 

 

Bid announced July; Alere went hostile Aug 5; closed Nov 2011 

 

Alexion Pharma (US) 

 

Taligen Therapeutics (US) 

 

$111.0 million 

 

Feb-11 

 

Alexion Pharma (US) 

 

Enobia Pharma (Canada) 

 

$610.0 million upfront and $470 million contingent on regulatory milestones 

 

Exp 1st-qtr 2012 

 

Alkermes (US) 

 

Elan Drug Technologies unit of Elan Corp (Ireland) 

 

$960 million cash and stock deal 

 

Sep-11 

 

Allergan (US) 

 

Vicept Thera (US) 

 

$275.0 million, of which $75 mill upfront 

 

Jul-11 

 

Allozyne (US) 

 

Poniard Pharma (US) 

 

Stock exchange deal 

 

Announced June 23. Deal called off Dec 2011 

 

Amgen (US) 

 

BioVex (US)   

 

$1.0 billion. Paid $435 million upfront with further $575 million in milestones 

 

Mar-11 

 

Amgen (US) 

 

Bergamo (Brazil) 

 

$215.0 million 

 

Apr-11 

 

Ancient Pharma (US) 

 

Timm Medical (US) 

 

Undisclosed 

 

Jan-11 

 

Apricus Biosciences (US) 

 

US subsidiary of Topotarget A/S (Denmark) 

 

$2.0 million plus $2 million stock based on milestones 

 

Dec-11 

 

Asahi Kasei Pharma (Japan) 

 

Artisan Pharma (US) 

 

Undisclosed 

 

Nov-11 

 

Astellas (Japan) 

 

Perseid Therapeutics (US) Buys Maxygen’s stake in JV 

 

$76.0 million 

 

May-11 

 

AstraZeneca (UK) 

 

Guangdong BeiKang Pharma (China) 

 

Undisclosed 

 

Exp 1st-qtr 2012 

 

Axcan (Canada) 

 

Mpex (US) 

 

$230.0 million 

 

Nov-11 

 

Baxter Int (US) 

 

Prism Pharma (US) 

 

$388.0 million of which $170 million upfront 

 

June 2-011 

 

Baxter Int (US) 

 

Baxo Corp (US) 

 

$380.0 million 

 

Nov-11 

 

Baxter Int (US) 

 

Synovis Life Technologies (US) 

 

$325.0 million 

 

Exp 1st-qtr 2012 

 

Biostar Pharma (US) 

 

Shaanxi Weinan (China) 

 

$9.6 million stock deal 

 

Oct-11 

 

Biotie Thera (Finland) 

 

Synosia Thera (Switz) 

 

$121.5 million 

 

Feb-11 

 

Biotie Thera (Finland) 

 

Newron Pharma (Italy) 

 

$60.8 million 

 

Deal cancelled 

 

BioTime (US) 

 

Glycosan Bio Systems (US) 

 

Undisclosed stock deal 

 

Mar-11 

 

BioTime (US) 

 

Cell Targeting (US) 

 

Undisclosed stock deal 

 

Jan-11 

 

Bluefish Pharma (Sweden) 

 

BMM Pharma unit of Medivir (Sweden) 

 

$6.0 million 

 

Aug-11 

 

Bristol-Myers Squibb (US) 

 

Amira Pharma (US) 

 

$325.0 million plus $150.0 million milestones 

 

Sep-11 

 

Celesio (Germany) 

 

OncoProd (Brazil) 60% stake 

 

Undisclosed 

 

Oct-11 

 

Cephalon (US) 

 

Gemin X Pharma (US) 

 

$225.0 million plus milestones of up to $300 million 

 

2011 

 

Cephalon (US) 

 

ChemGenex (Australia) 

 

$231.0 million 

 

2011 

 

Cornerstone Therapeutics (US) 

 

Cardiokine (US) 

 

Undisclosed 

 

Dec-11 

 

Cubist Pharma (US) 

 

Adolor Corp (US) 

 

$221 upfront plus contingent payment right worth up to $225 million 

 

Dec-11 

 

Cynapsus Therapeutics (Canada) 

 

Adagio Pharma (Canada) 

 

$5.55 million 

 

Dec-11 

 

Daiichi Sankyo (Japan) 

 

Plexxikon (US) 

 

$805.0 million 

 

Apr-11 

 

Elan (Ireland) 

 

Proteostasis Therapeutics (US) 

 

$20.0 million for 24% equity stake 

 

May-11 

 

Endo Pharma (US) 

 

American Medical Systems (US) 

 

$2.9 billion 

 

Jun-11 

 

Evotec (Germany) 

 

Kinaxo (Germany) 

 

$17 million 

 

Apr-11 

 

Ewopharma (Swiss) 

 

Newport Pharma subsid of Immdal (Ireland) 

 

Undisclosed 

 

Oct-11 

 

Farmsintez (Russia) 

 

Kevelt (Estonia) 

 

Undisclosed 

 

Jan-11 

 

Ferring Pharma (Swiss) 

 

Cytokine PharmaSciences (US) 

 

Undisclosed 

 

Oct-11 

 

Footstar (US) 

 

CPEX Pharma (US) 

 

$76.6 million 

 

Apr-11 

 

Forest Labs (US) 

 

Clinical Data (US) 

 

$1.2 billion 

 

Apr-11 

 

Fosun Pharma (China) 

 

Aleph Biomed (China) 75% stake 

 

$102.0 million 

 

Feb-11 

 

Galenica (Switz) 

 

Vifor Uriach, the joint venture with Grupo Uriach (Spain) 

 

Undisclosed 

 

Nov-11 

 

Gilead Sciences (US) 

 

Calistoga Pharma (US) 

 

$375.0 million plus possible $225 million in milestones 

 

Apr-11 

 

Gilead Sciences (US) 

 

Pharmasset (US) 

 

$11.0 billion 

 

Exp 1st-qtr 2011 

 

Grifols (Spain) 

 

Talecris Biotherapeutics (US) 

 

$3.4 billion 

 

Jun-11 

 

Hikma Pharma (Jordan) 

 

Unimark Remedies (India) – 25% stake 

 

$33.3 million 

 

May-11 

 

Hikma Pharma (Jordan) 

 

Baxter injectable generics business 

 

$112.0 million (First announced in 2010) 

 

May-11 

 

Hikma Pharma (Jordan) 

 

Hubei Haosun (China) minority stake 

 

$5.0 million 

 

2011 

 

Hikma Pharma (Jordan) 

 

Promopharm (Morocco) 

 

$111.2 million for 63.9% stake; intends to buy remainder 

 

Due end Jan 2012 

 

Histogenics (US) 

 

ProChon Biotech (Israel) 

 

Undisclosed stock-for-stock deal 

 

May-11 

 

Intrexon (US) 

 

Immunologix (US) 

 

Undisclosed 

 

Oct-11 

 

IS Pharma (UK) 

 

Helsinn Healthcare (Switz) Helsinn Birex unit in Ireland 

 

$6.0 million 

 

Feb-11 

 

Jazz Pharma (US) 

 

Azur Pharma (Irish) 

 

All stock merger with Jazz shareholders owning nearly 80%  

 

Dec-11 

 

Johnson & Johnson (US) 

 

Synthes (Switz) 

 

$21.3 billion 

 

EU Commission launched investigation Nov 2011, decision due Apr 2012 

 

Johnson & Johnson (US) 

 

J&J-Merck Consumer (US). Buys Merck & Co’s 50% stake in JV 

 

$175.0 million 

 

Sep-11 

 

Kyowa Hakko Kirin (Japan) 

 

ProStrakan (UK) 

 

$474.3 million 

 

Apr-11 

 

Kohlberg Kravis Roberts (US) 

 

Capsugel (US) a unit of Pfizer 

 

$2.38 billion 

 

Aug-11 

 

Ligand Pharma (US) 

 

CyDEX Pharma (US) 

 

$31.2 million, plus contingent payments 

 

Jan-11 

 

Eli Lilly (US) Elanco unit 

 

Janssen Pharma animal health business 

 

Undisclosed 

 

Jul-11 

 

Lupin (India) 

 

I’rom Pharma unit of I’rom Holdings (Japan) 

 

Undisclosed 

 

Nov-11 

 

Medicis (US) 

 

Graceway Pharma (US) 

 

$455.0 million 

 

Dec-11 

 

Medivir (Sweden) 

 

BioPhausia (Sweden) 

 

$90.8 million 

 

Jun-11 

 

Merck & Co (US) 

 

Inspire Pharma (US) 

 

$430.0 million 

 

May-11 

 

Merck KGaA (Germany) 

 

Beijing Skywing (China) 

 

$18.2 million 

 

Jan-11 

 

Merck KGaA (Germany) 

 

Microbiology business of Biotest AG (Germany) 

 

Undisclosed 

 

Aug-11 

 

Menarini (Italy) 

 

Invida (Singapore) 

 

Undisclosed) 

 

Nov-11 

 

Mitsui & Co (Japan) 

 

Mercian (Japan) pharma and chemical business 

 

Undisclosed 

 

Jun-11 

 

NeoStem (US) 

 

Progenitor Cell Therapy (US) 

 

About $20.0 million 

 

Oct-11 

 

Nitto Denko (Japan) 

 

Avecia Biotech (US) 

 

Undisclosed 

 

Feb-11 

 

Novartis (Switz) 

 

Genoptix (US) 

 

$470.0 million 

 

Jun-11 

 

Novartis (Switz) 

 

Zhejiang Tianyuan (China) – 85% stake 

 

$125.0 million 

 

Mar-11 

 

Novelos Thera (US) 

 

Cellectar (US) 

 

Stock deal 

 

Apr-11 

 

Nycomed (Switz) 

 

Lab Farmacol (Colombia) 

 

Undisclosed 

 

Jun-11 

 

OPKO Health (US) – controlled by Teva 

 

FineTech Pharmaceutical (Israel) 

 

$27.5 million 

 

Dec-11 

 

Paladin Labs (Canada) 

 

Labopharm (Canada) 

 

$20.6 million 

 

Oct-11 

 

Par Pharmaceutical (US) 

 

Edict Pharmaceuticals (India) 

 

$37.6 million plus assumption of debt 

 

Nov-11 

 

Par Pharma (US) 

 

Anchen Pharma (US) 

 

$410.0 million 

 

Nov-11 

 

Perrigo (US) 

 

Paddock Labs (US) 

 

$540.0 million 

 

Jul-11 

 

Pfizer (US) 

 

Ferrosan (Denmark) Consumer health unit 

 

Undisclosed 

 

Dec-11 

 

Pfizer (US) 

 

Icagen (US) 

 

$56.0 million enterprise value 

 

Oct-11 

 

Pfizer (US) 

 

Excaliard Pharma (US) 

 

Undisclosed 

 

Dec-11 

 

Pharmstandard (Russia) 

 

PJSC Biolek (Russia) 

 

Undisclosed 

 

Jan-11 

 

Qiagen (Netherlands) 

 

Cellestis (Australia) 

 

$355.0 million 

 

Sep-11 

 

Qiagen (Netherlands) 

 

Ipsogen (France) 

 

$101.0 million 

 

Jul-11 

 

Recordati (Italy) 

 

Frik Ilac (Turkey) 

 

$130 million 

 

Sep-11 

 

Repligen (US) 

 

Novozymes Biopharma Sweden unit of Denmark’s Novozymes 

 

$22.7 upfront and $5.6 million milestones 

 

Dec-11 

 

Roche (Swiss) 

 

PVT Probenverteiltecknik (Germany) 

 

$90.0 million, plus performance-related milestone 

 

May-11 

 

Roche (Swiss) 

 

mtm laboratories (Germany) 

 

$268.4 million 

 

Aug-11 

 

Roche (Swiss) 

 

Anadys Pharma (US) 

 

$230.0 million 

 

Nov-11 

 

Rxi Pharma (US) 

 

Apthera (US) 

 

$7.2 million plus milestones 

 

Apr-11 

 

Salix Pharma (US) 

 

Oceana Therapeutics (US) 

 

$300.0 million 

 

Dec-11 

 

Sanofi (France) 

 

Genzyme (US) 

 

$21.1 billion plus CVR 

 

Apr-11 

 

Sanofi (France) 

 

OTC business of Universal Medicare (India) 

 

$100 million (Est) 

 

Nov-11 

 

Santen Pharma (Japan) 

 

Novagali (France) 

 

50.55% stake with aim of buying remained for around $135 million 

 

First tranche completed Oct 2011 

 

SciClone Pharma (US) 

 

NovaMed Pharma (China) 

 

$104.8 million cash and shares, with $61.8 upfront 

 

Apr-11 

 

Shire (Ireland) 

 

Advanced BioHealing (US) 

 

$750.0 million 

 

Jun-11 

 

Sinclair IS (UK) 

 

Advanced Bio-Technologies (US) 

 

$32.8 million 

 

Ann Dec 8, close exp 1st-qtr 2011 

 

Sinclair Pharma (UK) 

 

IS Pharma (UK) 

 

Est $208 million stock deal merger 

 

2011 

 

SOHM (US) 

 

Novatrend Medicament (India) 

 

Undisclosed 

 

Nov-11 

 

STADA Arzneimittel (Germany) 

 

Generics business of Spirig Pharma (Switz) 

 

$109.2 million 

 

Exp 1st-qtr 2012 

 

Sucampo Pharma (US) 

 

Sucampo AG (Switz) and Sucampo AG Japan (Japan) 

 

$80.0 million 

 

Jan-11 

 

Sun Pharma (India) 

 

Caraco Pharma (US) Remaining 24.2% shares 

 

$5.25/share 

 

Jun-11 

 

SuperGen (US) 

 

Astex Therapeutics (UK) 

 

$25.0 million plus $30 million deferred 

 

Jul-11 

 

Synageva BioPharma (US) 

 

Trimeris (US) 

 

All stock deal for Trimeris which has market cap of $63.6M 

 

Jul-11 

 

Takeda (Japan) 

 

Fate Therapeutics (US) Unspecified stake 

 

Undisclosed 

 

May-11 

 

Takeda (Japan) 

 

Nycomed (Switz) 

 

$13.68 billion 

 

Sep-11 

 

Takeda (Japan) 

 

Intellikine (US) 

 

$190.0 million up front plus $120 million in contingent milestones 

 

Exp Jan 2012 

 

Teva Pharma Industries (Israel) 

 

Infarmasa (Peru) 

 

Undisclosed 

 

Jan-11 

 

Teva Pharma Industries (Israel) 

 

Cephalon (US) 

 

$6.8 billion 

 

Oct-11 

 

Teva (Israel) 

 

Taiyo Pharma (Japan) 100% stake 

 

$934.0 million 

 

Jul-11 

 

Teva (Israel) 

 

CureTech (Israel) increases equity stake to 75% 

 

$19.0 million plus $50 million R&D funding 

 

Oct-11 

 

Teva (Israel) 

 

Teva-Kowa-Pharma, a joint venture with Kowa (Japan) 

 

$150.0 million for Kowa’s 50% share 

 

Oct-11 

 

The Medicines Company (US) 

 

GeNO (US) undisclosed non-majority stake 

 

Undisclosed 

 

Dec-11 

 

Valeant Pharma (Canada) 

 

PharmaSwiss (Switz) 

 

$480.0 million 

 

Mar-11 

 

Valeant Pharma (Canada) 

 

Sanitas (Lithuania) 

 

$444.4 million 

 

Aug-11 

 

Valeant (Canada) 

 

Dermik (Canada & US) subsidiary of Sanofi (France) 

 

$422.5 million 

 

Dec-11 

 

Valeant (Canada) 

 

Ortho Dermatologics (unit of Johnson & Johnson)  

 

$345.0 million 

 

Ann july; FTC appro gained Dec 12 2011 

 

Valeant (Canada) 

 

Afexa Life Sciences (Canada) 

 

$76.9 million 

 

Completed Dec 2011. Ann. Aug 31 in Battle with Paladin for control 

 

Valeant (Canada) 

 

iNova (Australia) 

 

$703.8 million (including A$75 million contingent payment 

 

Dec-11 

 

Valeant (Canada) 

 

ISTA Pharma (US) 

 

$327.0 million 

 

Ann Nov but rejected, and Valeant went hostile Dec 2011 

 

ViroPharma (US) 

 

DuoCort Pharma (Sweden) 

 

$164.0 million 

 

Nov-11 

 

Watson Pharma (US) 

 

Specifar Pharma (Greece) 

 

$562.0 million plus 400 million-euro contingent 

 

May-11 

 

XTL Biopharma (Israel) 

 

MinoGuard (Israel) technology 

 

Undisclosed 

 

Nov-11 

 

Zydus Cadila (India) 

 

Nesher Pharma generics unit of K-V Pharmaceutical US) 

 

$60.0 million 

 

Aug-11 

 

Zydus Cadila (India) 

 

Biochem (India) 

 

Undisclosed 

 

Dec-11 

 

 

* Where not announced in US dollars, transaction values are calculated at the exchange rates prevailing at the time of announcement.

4652 total views, 0 today

Tools


  • No ads viewed yet.